Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MGNX 
MacroGenics Inc (MGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: MGNX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.75
1 Year Target Price $3.75
| 2 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 65.75% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 116.30M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 9 | Beta 1.61 | 52 Weeks Range 0.99 - 5.10 | Updated Date 10/24/2025 |
52 Weeks Range 0.99 - 5.10 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -21.99% | Operating Margin (TTM) -165.27% |
Management Effectiveness
Return on Assets (TTM) -21.84% | Return on Equity (TTM) -69.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31157248 | Price to Sales(TTM) 0.7 |
Enterprise Value -31157248 | Price to Sales(TTM) 0.7 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -1.54 | Shares Outstanding 63205703 | Shares Floating 52560599 |
Shares Outstanding 63205703 | Shares Floating 52560599 | ||
Percent Insiders 3.25 | Percent Institutions 76.6 |
Upturn AI SWOT
MacroGenics Inc
Company Overview
History and Background
MacroGenics Inc. was founded in 2000. It is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
Core Business Areas
- Oncology Therapeutics: Focuses on developing antibody-based therapies for various cancer types. Includes bispecific antibodies and antibody-drug conjugates (ADCs).
- Autoimmune Disorders: Explores the use of its technology platform to create therapies for autoimmune diseases.
Leadership and Structure
The leadership team includes Scott Koenig, M.D., Ph.D. (President and CEO). The organizational structure is typical of a biopharmaceutical company, with departments focused on research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Margenza (margetuximab-cmkb): An Fc-engineered monoclonal antibody approved for HER2-positive metastatic breast cancer. Competitors include Roche's Herceptin and Perjeta; Daiichi Sankyo and AstraZeneca's Enhertu. Market share data is difficult to precisely determine, but Margenza is competing in a market dominated by established therapies. Revenue data is available in MacroGenics' financial reports.
- Tebentafusp: Approved for treatment of unresectable or metastatic uveal melanoma. Competitors are sparse given the niche nature of the disease. Approvals depend on the territories. Tebentafusp is co-marketed.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The oncology segment is highly competitive, with many companies developing novel therapies.
Positioning
MacroGenics Inc. is positioned as an innovative biopharmaceutical company focused on antibody-based therapeutics. Its competitive advantage lies in its proprietary DART (Dual-Affinity Re-Targeting) platform for developing bispecific antibodies.
Total Addressable Market (TAM)
The total addressable market (TAM) for cancer therapeutics is in the hundreds of billions of dollars. MacroGenics targets specific segments within this market, such as HER2-positive breast cancer and uveal melanoma. Their positioning within the TAM depends on the success of their current products and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary DART platform for bispecific antibodies
- Approved products in oncology
- Strong research and development capabilities
- Partnerships with larger pharmaceutical companies
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Dependence on successful clinical trial outcomes
- Competition from larger, more established companies
Opportunities
- Expansion of approved product indications
- Development of new therapies using the DART platform
- Strategic collaborations and partnerships
- Acquisition of complementary technologies or assets
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars or novel therapies
- Patent expirations
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- RHHBY
- AZN
- MRK
Competitive Landscape
MacroGenics' has less market share than the main competitors, but has its own target. It leverages its DART platform for new therapies, but faces competition from larger companies with more resources. DART platform offers potential advantage through differentiated MOA.
Growth Trajectory and Initiatives
Historical Growth: MacroGenics' historical growth has been driven by the development and approval of its products. The company's growth trajectory depends on the success of its pipeline and its ability to expand into new markets.
Future Projections: Future growth depends on analyst estimates for Margenza and Tebentafusp sales, as well as the potential approval of new products in the pipeline. Analyst reports provide revenue projections and target prices.
Recent Initiatives: Recent initiatives include ongoing clinical trials for existing products, development of new bispecific antibodies, and strategic partnerships to expand market reach.
Summary
MacroGenics is a biopharmaceutical company with innovative technology and approved products in oncology. It needs to expand its product portfolio and successfully navigate the high-risk, high-reward nature of drug development. Competition from larger companies remains a significant challenge. Strong clinical trial results and successful commercialization of its products are critical for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MacroGenics Inc. SEC Filings
- Analyst Reports
- Company Website
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise. Investment decisions should be based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MacroGenics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2013-10-10 | CEO, President & Director Mr. Eric Blasius Risser | ||
Sector Healthcare | Industry Biotechnology | Full time employees 341 | Website https://www.macrogenics.com |
Full time employees 341 | Website https://www.macrogenics.com | ||
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.